Latest On Bio-Path Holdings, Inc (BPTH):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 21:27 EST | News | Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript | N/A |  |
| 2023-05-12 07:11 EST | News | Bio-Path GAAP EPS of -$0.66 misses by $0.34 | N/A | |
| 2023-03-31 18:11 EST | News | Bio-Path GAAP EPS of -$1.91 misses by $1.46 | N/A | |
| 2023-03-31 18:11 EST | News | Bio-Path Holdings Inc. (BPTH) Q4 2022 Earnings Call Transcript | N/A | |
| 2022-11-15 16:27 EST | News | Bio-Path GAAP EPS of -$0.49 misses by $0.03 | N/A | |
About Bio-Path Holdings, Inc (BPTH):
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen- read more...A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
General
- Name Bio-Path Holdings, Inc
- Symbol BPTH
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 10
- Last Split Factor1:20
- Last Split Date2019-01-18
- Fiscal Year EndDecember
- IPO Date2008-03-04
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.biopathholdings.com
Valuation
- Price/Book (Most Recent Quarter) 3.41
- Enterprise Value EBITDA 0.22
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.98
- Next Year EPS Estimate -$1.97
- Next Quarter EPS Estimate -$0.75
- Return on Assets -35%
- Return on Equity -60%
- Earnings Per Share -$6.19
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 49.26 million
- EBITDA -8080000
- Analyst Target Price $11.5
- Book Value Per Share $3.32
Share Statistics
- Shares Outstanding 6.95 million
- Shares Float 6.9 million
- % Held by Insiders 102%
- % Held by Institutions 7.77%
- Shares Short 111802
- Shares Short Prior Month 474210
- Short Ratio 0.02
- Short % of Float 2%
- Short % of Shares Outstanding 2%
Technicals
- Beta 2.21
- 52 Week High $9.4
- 52 Week Low $3.12
- 50 Day Moving Average 6.52
- 200 Day Moving Average 4.54
Dividends
- Dividend Date 2019-01-18
- ExDividend Date N/A
- Dividend Yield 0%
Bio-Path Holdings, Inc (BPTH) Dividend Calendar:
BPTH's last dividend payment was made to shareholders on January 18, 2019.
Bio-Path Holdings, Inc (BPTH) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Bio-Path Holdings, Inc (BPTH) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 1.54 million | N/A | N/A | 2.01 million | 1.29 million |
| Income Before Tax | -2.55 million | N/A | N/A | -3.32 million | -2.39 million |
| Selling General Administrative | 1.01 million | N/A | N/A | 1.34 million | 1.12 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -2.55 million | N/A | N/A | -3.31 million | -2.41 million |
| Operating Income | -2.55 million | N/A | N/A | -3.34 million | -2.41 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 24000 |
| Net Income From Continuing Operations | -2.55 million | N/A | N/A | -3.32 million | -2.39 million |
| Net Income Applicable to Common Shares | -2.55 million | -2.97 million | -2.04 million | N/A | -2.39 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | 199000 | -364000 | N/A | 19000 | 141000 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 7.29 million | 169000 |
| Change to Operating Activities | 235000 | -1.23 million | N/A | -76000 | -12000 |
| Change in Cash | N/A | N/A | -2.54 million | 5.04 million | -1.72 million |
| Total Cash from Operating Activities | -2.35 million | -3.48 million | -2.54 million | -2.25 million | -1.89 million |
| Depreciation | N/A | N/A | 37000 | 39000 | 36000 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 143000 | 119000 | N/A | 162000 | 184000 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 1.41 million | N/A | N/A | 1.89 million | 1.57 million |
| Total Stockholder Equity | 15.07 million | N/A | N/A | 17.93 million | 21.09 million |
| Other Current Liabilities | 94000 | N/A | N/A | N/A | N/A |
| Total Assets | 16.48 million | N/A | N/A | 19.83 million | 22.66 million |
| Common Stock | 5000 | 4000 | 4000 | N/A | 4000 |
| Other Current Assets | 2.2 million | 2.26 million | N/A | 538000 | 1.56 million |
| Retained Earnings | -67.22 million | -64.67 million | -61.7 million | -59.66 million | -56.34 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | 13.76 million | N/A | N/A | 17.89 million | 20.43 million |
| Total Current Liabilities | 1.17 million | 1.43 million | N/A | 1.59 million | 1.24 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 231000 | 558000 | 596000 | N/A | 670000 |
| Total Current Assets | 15.96 million | 14.32 million | N/A | 19.19 million | 21.99 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 15.07 million | 13.19 million | 16.01 million | N/A | 21.09 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 1.08 million | 614000 | N/A | 818000 | 486000 |
Bio-Path Holdings, Inc (BPTH) Chart:
Bio-Path Holdings, Inc (BPTH) News:
Below you will find a list of latest news for Bio-Path Holdings, Inc (BPTH) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Bio-Path Holdings, Inc (BPTH) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest BPTH Trades:
Bio-Path Holdings, Inc (BPTH) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | DEF 14A (Other definitive proxy statements) | |
| 2020-11-05 | DEFA14A (Additional definitive proxy soliciting materials and Rule 14(a)(12) material) | |
| 2020-10-22 | 8-K (Current report) | |
| 2020-09-10 | 8-K (Current report) | |
| 2020-08-14 | 8-K (Current report) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-07-14 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-14 | 8-K (Current report) | |
| 2020-07-06 | 8-K (Current report) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-29 | 8-K (Current report) | |
| 2020-05-15 | 8-K (Current report) | |
| 2020-05-14 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-05-14 | 8-K (Current report) | |
| 2020-04-27 | 8-K (Current report) | |
| 2020-04-14 | 8-K (Current report) | |
| 2020-03-31 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-03-31 | 4 (Statement of changes in beneficial ownership of securities) | |
Bio-Path Holdings, Inc (BPTH) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Bio-Path Holdings, Inc (BPTH). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 102%
Institutional Ownership: 777%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-01-18 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Sell | 0.00 | 129,298.00 | | ||
| 2019-01-18 | ARMISTICE CAPITAL, LLC | 10% Share Holder | Sell | 64,457.00 | 2.66 | 171,642.55 | 129,298.00 | |